Spencer Pharmaceutical Releases Scientific Results
November 17 2010 - 9:00AM
Marketwired
Spencer Pharmaceutical Inc. (PINKSHEETS: SPPH) announced today that
it has released some of its scientific results.
The company states that chronic inflammation is closely related
to many diseases and conditions associated with aging as well as
arthritis, gastric reflux disease, colitis, some forms of cancer,
Alzheimer's disease, immune dysfunction, etc. There is a great need
for effective treatments that will be simple with no adverse side
effects.
Generally, Ibuprofen (OTC) is rapidly absorbed following oral
administration, and possesses a plasma half-life of approximately 2
hours with 80 % of the administered dose excreted in urine.
Consequently, the immediate-release dosage of ibuprofen is 200 mg
every 4-6 h, with a maximum dosage of 1200 mg over 24 hours. In
simple language, there is a big demand on the market for slow
release Ibuprofen.
"Spencer Pharmaceutical has developed such a slow release and
unique formulation for NSAIDs controlled release, particularly
Ibuprofen, under direct compression on monolithic tablet format,
which are able to deliver immediately an effective dosage of the
molecule and the remained dosage over a delayed period of 8-10
hours," stated Dr. Max Arella, CEO of Spencer Pharmaceutical Inc.
Furthermore "The matrix (excipient) is based on natural molecules
and stabilized under ionic forms. All ingredients are 100 % GRAS
(generally approved as safe) and already approved as acceptable
substances by FDA," pointed out Dr. Arella.
The company also points out, in vitro dissolution showed the
novel monolithic tablet (600 mg) of ibuprofen is rapidly delivered
in simulated gastric fluid (SGF, pH 2.0) with approximately 25 %
released during the first hour and the remaining dosage of
ibuprofen is sustained for released over the remaining 10 hours.
The easy and non-expensive matrix developed by Spencer
Pharmaceutical is currently being submitted for patent
protection.
"We are excited by these new results and we are confident that
many applications will be found for this new matrix developed by
our scientists," commented Dr. Max Arella, CEO of Spencer
Pharmaceutical.
About Spencer Pharmaceutical Inc.
Spencer Pharmaceutical Inc. is a US-based Pharmaceutical
Research and Development Corporation, which is developing
innovative drug release and absorption systems for the treatment of
metabolic diseases such as diabetes and metabolic syndrome.
Important Information About Forward-Looking Statements in this
press release may be "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995.
Words such as "anticipate," "believe," "estimate," "expect,"
"intend" and similar expressions, as they relate to the company or
its management, identify forward-looking statements. These
statements are based on current expectations, estimates and
projections about the company's business based, in part, on
assumptions made by management. These statements are not guarantees
of future performance and involve risks, uncertainties and
assumptions that are difficult to predict. Therefore, actual
outcomes and results may, and probably will, differ materially from
what is expressed or forecasted in such forward-looking statements
due to numerous factors, including those described above. In
addition, such statements could be affected by risks and
uncertainties related to the exploration for and development of
mineralized material, product demand, market and customer
acceptance, competition, pricing and development difficulties, as
well as general industry and market conditions and growth rates and
general economic conditions. Any forward-looking statements speak
only as of the date on which they are made, and the company does
not undertake any obligation to update any forward-looking
statement to reflect events or circumstances after the date of this
release. Information on the Company's website does not constitute a
part of this release.
Contact: Dr. Max Arella CEO Spencer Pharmaceutical Inc.
Tel. 1+(617) 973-5017
Spencer Pharmaceutical (CE) (USOTC:SPPH)
Historical Stock Chart
From Sep 2024 to Oct 2024
Spencer Pharmaceutical (CE) (USOTC:SPPH)
Historical Stock Chart
From Oct 2023 to Oct 2024